News & Events

• November 9, 2021
  

  C-Path Joins New Coalition to Improve Patient Care and Address Unmet Medical Needs through Community-Level Clinical Trials

  WASHINGTON and TUCSON, Ariz., November 9, 2021 — Launching today, the Advancing Clinical Trials at the Point of Care (ACT@POC) Coalition will generate quality clinical research evidence in real time to better evaluate treatments and therapeutics, including those to treat COVID-19. The Coalition will engage a broader, more diverse group of patients and providers and develop digital health tools that make clinical trials simpler to run and more accessible to patients.

• March 31, 2021
  

  Cures Within Reach Names CURE ID as 2021 Patient Impact Awardee

    Cures Within Reach, a global nonprofit leading the use of repurposing research to help improve patients’ lives, has awarded CURE ID at the FDA and NCATS/NIH as the recipient of the 2021 Golan Christie Taglia Patient Impact Philanthropy Award part of its 2021 Patient Impact Award recipients of the Global Health Repurposing Awards. C-Path’s Cure Drug Repurposing Collaboratory (CDRC),...
• February 4, 2021
  

  C-Path Appoints Co-Directors to CURE Drug Repurposing Collaboratory Advisory Committee

  TUCSON, Ariz., February 4, 2021 — Critical Path Institute (C-Path) today has announced the appointments of David Fajgenbaum, M.D., M.S., M.B.A., and Marco Schito, Ph.D., as co-directors of the advisory committee for C-Path’s CURE Drug Repurposing Collaboratory (CDRC) program.

• June 23, 2020
  

  C-Path Launches CURE Drug Repurposing Collaboratory to Accelerate Identification of New Uses of Existing Drugs to Treat Infectious Diseases, Including COVID-19

  TUCSON, Ariz., June 23, 2020 — As millions of patients struggle with diseases that lack adequate treatments, there is a critical need to understand how existing drugs can be used in new ways to improve clinical outcomes. Health care professionals use drugs in novel ways as a potential life-saving intervention when no specific approved therapies are available. However, without the ability to share these experiences in a systematic manner, the clinical and research communities cannot benefit from lessons learned.

• June 11, 2020
  

  From the Regulatory Affairs Professional Society (RAPS): FDA’s CURE ID app gets a COVID-19 refresh

  An online case reporting platform has been optimized for COVID-19 and will be the springboard for a new public-private drug repurposing collaboration.

  The CURE ID online platform was developed to allow clinicians to report off-label uses of drugs to treat infectious diseases, with the goal of generating hypotheses for further study of difficult-to-treat infectious diseases. The internet repository of these cases can also be accessed by clinicians and other users, with the option to view aggregated datasets as well as the individual case reports. The platform can be used via a computer browser or Apple and Android-based smartphone apps. Full article here.